Search

Purpose: To report a series of severe corneal changes following intravitreal injection of bevacizumab (Avastin) for age-related macular degeneration. Design: Retrospective noncomparative case series. Methods: The authors retrospectively reviewed the corneal changes that developed after the procedure in 1200 (460 patients) intravitreal injections of bevacizumab. Results: Five significant corneal changes (1.1%) occurred in these patients within the 1st postinjection week. The severe corneal changes included corneal infiltrative keratitis ( n = 2) and corneal stromal edema and descemet folds ( n = 3). The findings depended on clinical examination and biomicroscopic and confocal evaluation. In terms of causality assessment, no rechallenge was possible. The appropriate treatment was applied and recovery was achieved in all patients during the follow-up period. Conclusions: Intravitreal injection of bevacizumab may cause corneal changes. The safety and effects of bevacizumab on the cornea should be evaluated in detail. [ABSTRACT FROM AUTHOR]

Purpose: To report a case of presumed Eales disease that showed regression of retinal neovascularization after the use of intravitreal bevacizumab. Design: Retrospective, interventional case report. Methods: Broad retinal neovascularization in a patient with presumed Eales disease did not regressed despite adequate photocoagulation treatment, and bevacizumab (1.25 mg) was injected intravitreally. The patient was followed up for 1 year. Results: One week after injection, fluorescein angiography demonstrated dramatic regression of retinal neovascularization. After 12-months, visual acuity was improved and no signs of recurrence were observed. Conclusion: Intravitreal bevacizumab may be effective as an adjunctive treatment of retinal neovascularization in patients with Eales disease. [ABSTRACT FROM AUTHOR]